This page features ACC's full coverage of the latest science from Transcatheter Cardiovascular Therapeutics (TCT) 2026, taking place Oct. 31 to Nov. 3, 2026 in San Diego, CA.

A new international expert consensus document refines and updates how heart failure is identified and classified, aiming to improve prevention, diagnosis and management of heart failure worldwide.

People with cardiometabolic disorders—such as obesity, diabetes and heart disease—could increase their chances of living longer by adopting a healthy plant-based diet, according to a study being ...

In this week’s View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) ...

This page features ACC's coverage of the latest science from ESC Congress 2024 – Aug. 30th through Sept. 2nd – including trial summaries, news stories and more.

Earn continuing education credits Prepare for initial and continuous certification Stay current with the latest clinical science and guidelines Connect with peers through meetings, events and ...

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...

A robust body of observational and Mendelian randomization data establishes a causal relationship between elevated Lp(a) and ASCVD, ischemic stroke and calcific aortic valve stenosis (CAVS). 3 A ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

Among community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result ...

In patients with left-sided infective endocarditis a clinical response-tailored antibiotic strategy shortened antibiotic duration by two weeks compared with standard therapy, with no major safety ...